A Phase I Study to Determine the Pharmacokinetics of Buspirone from a Metered Dose Transdermal System (MDTS) in anxiety
Phase 1
Completed
- Conditions
- AnxietyMental Health - Anxiety
- Registration Number
- ACTRN12605000525684
- Lead Sponsor
- Acrux DDS Pty Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Healthy volunteers
Exclusion Criteria
No exclusion criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Buspirone's 5-HT1A receptor activation via transdermal delivery in anxiety?
How does the MDTS transdermal system compare to oral Buspirone in pharmacokinetic profiles and anxiolytic efficacy?
Which biomarkers correlate with Buspirone response in transdermal versus systemic administration for anxiety disorders?
What adverse events are associated with Buspirone transdermal patches in Phase I trials and how are they managed?
How do Acrux DDS's transdermal technologies for Buspirone compare to competitor approaches in anxiolytic drug delivery?